Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FUT4/CD15 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FUT4 Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for enzymatic assays. |
View FUT4 Products |
| Gene Delivery | FUT4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines to study Lewis X (CD15) surface expression. |
View FUT4 Products |
| Benchmark Ab | Anti-CD15 Recombinant Antibody Recombinant positive control for FACS, IHC, and cell-binding validation. |
View FUT4 Products |
| Validator | FUT4 siRNA Set For knockdown verification in target-validation assays. |
View FUT4 Products |
| Related Target A | FUT7 Synergistic glycosyltransferase involved in sialyl Lewis X (sLeX) synthesis; critical for selectin-mediated metastasis. |
View FUT7 Products |
| Related Target B | FUT3 Key family member for selectivity screening to avoid off-target glycosylation effects. |
View FUT3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily Selectivity (FUT3/FUT5/FUT6 vs. FUT4) | Highly purified recombinant FUT family panel strictly verified by Mass Spectrometry. |
| Cell-Surface CD15 Conformation Preservation | Lentivirus premade particles for stable cell line construction to enable native flow cytometry screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies (biosimilars) included |
| False Positives in Glycans | Validated siRNA sets included for specific FUT4 gene knockdown verification |
Live FUT4/CD15 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FUT4/CD15 therapeutics is intensifying, with major players shifting focus from traditional diagnostics to targeted therapeutics including CAR-T, ADCs, and small-molecule glycosyltransferase inhibitors. As first-generation therapies reach the clinic, the next wave of R&D is targeting cancer stem cell (CSC) elimination and the disruption of selectin-mediated tumor cell extravasation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Academic/Biotech consortia | Solid Tumors, Inflammatory Diseases | Enzymatic activity assays (Need high-purity recombinant FUT4) |
| CAR-T / Cell Therapy | Clinical-stage biotechs | Hodgkin's Lymphoma, AML | Target cell validation (Need Lentivirus for stable CD15+ cell lines) |
| Monoclonal Antibody / ADC | Oncology-focused pharma | Non-Small Cell Lung Cancer (NSCLC) | Internalization and binding assays (Need CD15 benchmark antibodies) |